*Sponsored by Nutriband Inc.
Krypton Street Announces Coverage On Nutriband Inc. (NASDAQ: NTRB) Starting Right Now—Wednesday, July 2, 2025
(NTRB) Comes Backed By Several Potential Catalysts—But Here's What We Can Tell You Right Now…
Just Yesterday (NTRB) Was Added To Several Russell Indexes Increasing Its Visibility Among Institutional Radars.
Noble Capital Markets Recently Raised Their Target On (NTRB) To $15 Citing Updated FY2027 Eps Projections And Market Positioning.
With Under 4.5M Shares Listed In The Float (NTRB) Could See Significant Swing Potential If Demand Begins To Shift.
And The Last Two Times We Covered (NTRB) It Moved Approximately 31% And 42% Inside Of Very Short Periods.
Pull Up (NTRB) This Morning While It's Still Early…
July 2, 2025 Dear Reader, News out from (NTRB) has us sitting up and taking notice right now. Breaking: 25% Preferred Dividend Declared as AVERSA FDA Filing Targeted Shareholders on record as of July 25, 2025 will receive a 25% preferred stock dividend, with one preferred share for every four common shares, payable August 5. These preferred shares will automatically convert to common shares following FDA approval of AVERSA™ Fen-tan-yl. If not converted, they will qualify for annual cash dividends from company profits at the Board's discretion. CEO Gareth Sheridan emphasized the company's commitment to building shareholder value as it moves closer to FDA submission and commercialization of AVERSA Fen-tan-yl, highlighting momentum from the recent manufacturing scale-up with Kindeva. If you missed my earlier report, now's the time to get up to speed on (NTRB). After Monday's profile reached $13.71, moving approximately 31% from Friday's $10.44 close—and following last Thursday night's profile that moved around 94% in under 24 hours—we're now turning our focus to Nutriband Inc. (NASDAQ: NTRB) this morning, Wednesday, July 2, 2025. Little-known companies can remain under the radar until the right potential catalysts arrive. When they do, attention can shift almost instantly. That's exactly what's happening with (NTRB) today. A series of recent developments has brought (NTRB) to the forefront, with momentum that's hard to overlook. But keep in mind, (NTRB) has a very limited float with less than 4.5 Mln shares listed as available to the public. A few weeks ago, we highlighted (NTRB) as it went from a $6.50 close on Friday, May 30, to $8.55 by Monday, June 2—an approximate 31% move in just days. Before that, we covered it as it went from $5.68 to $8.11 within 24 hours, for an approximate 42% move. Recently, Robert LeBoyer, Senior Vice President and Equity Research Analyst at Noble Capital Markets, raised his target on (NTRB) to $15, which suggests over 90% upside potential from yesterday's $7.86 open. 
Just yesterday, (NTRB) was officially added to several Russell indexes, including growth-focused benchmarks, as part of the 2025 reconstitution. This inclusion could have the potential to draw in the attention of institutional funds and index strategies that track these widely followed benchmarks, expanding market visibility at a pivotal point for the company. On the technical side, Barchart highlighted (NTRB) with 13 out of 13 bullish signals across short-, medium-, and long-term indicators, underscoring the momentum potential in its trend. Positioning for Commercial Readiness
This is a company with a clear, focused mission: improving the safety of transdermal delivery. Its lead product, AVERSA™ Fen-tan-yl, isn't just another patch—it's designed as an abuse-deterrent transdermal system that could reshape how these therapies are delivered to those who need them while reducing the risks of misuse. In June, (NTRB) and its partner Kindeva announced they had completed the commercial manufacturing process scale-up for AVERSA Fen-tan-yl, marking a pivotal step forward. This move means the company is preparing to file its Investigational (IND) application with the FDA for clinical testing—a necessary gateway to commercial readiness 
Patent Protection Across Key Markets
(NTRB)'s AVERSA™ technology is protected by a broad patent portfolio in 46 countries, including the United States, Europe, Japan, Korea, and China. This coverage strengthens the foundation for its transdermal abuse-deterrent platform, which can be applied to a range of dr-ugs with potential misuse risks, including opi-oids and stimulants. This innovation matters, particularly in a landscape where transdermal fen-tan-yl remains a necessary treatment, yet carries a high risk of misuse. AVERSA aims to address this gap without restricting patient access. Milestone Sets Stage for Trials
Recently, Gareth Sheridan, CEO of Nutriband, emphasized the significance of completing the manufacturing scale-up, calling it "an important step toward the development of a commercially viable product and eventual NDA filing." He underscored how the milestone demonstrates the compatibility of AVERSA technology with established manufacturing processes, providing a clear path toward clinical testing and future commercial rollout. For (NTRB), only a single Phase 1 study is required under the FDA's 505(b)(2) pathway, and the trial is designed specifically to demonstrate that the patch is less preferable for misuse compared to conventional fen-tan-yl patches—an approach considered a low-risk step toward approval. Recent Headlines:
- June 3, 2025: The USPTO issued a U.S. patent further expanding coverage for Nutriband's AVERSA technology.
- June 18, 2025: Nutriband and Kindeva completed the commercial manufacturing scale-up for AVERSA Fen-tan-yl, preparing for IND filing and clinical testing.
- The technology holds the potential to become the first abuse-deterrent pain patch on the market, with peak annual U.S. sales estimates ranging from $80M to $200M, according to company statements.
Why We Have All Eyes On (NTRB) Right Now
This is a pivotal moment for (NTRB). It has moved from a concept to a tangible pathway toward market readiness, backed by a partner with global manufacturing capabilities and a clear regulatory roadmap. The addressable need for safer transdermal therapies remains significant, and the technical and regulatory progress seen over the past weeks positions (NTRB) in a stronger light than many might realize. If you want to follow a company aligned with a clear mission, credible technology, and a tangible timeline for its next steps, (NTRB) deserves a place on your screen right now. Now's the time to keep an eye on (NTRB) as this story continues to unfold. 
7 Reasons Why (NTRB) Just Hit Our Radar This Morning
—Wednesday, July 2, 2025
1. New Index Addition: just yesterday, (NTRB) was added to several Russell indexes, which has the potential to increase its visibility among institutional radars.
2. Limited Float: with under 4.5M shares listed in the float, (NTRB) could witness the potential for significant swings if demand begins to suddenly change.
3. Analyst Raise Target: Noble Capital Markets has raised their target on (NTRB) to $15, citing updated FY2027 EPS projections and market positioning.
4. Recent Momentum: during our last two coverage announcements, (NTRB) has moved approximately 31% and 42% in short windows, reflecting past momentum during key moments. 5. Milestone Manufacturing Step: in June, (NTRB) and partner Kindeva completed scale-up for AVERSA Fen-tan-yl, preparing for FDA filing. 6. Strong Technical Signals: Barchart recently highlighted (NTRB) with 13 out of 13 bullish signals across short-, medium-, and long-term indicators, underscoring consistent momentum in its trend. 7. Patent-Backed Platform: with coverage in 46 countries, (NTRB) holds broad protection for its AVERSA™ transdermal technology. Pull Up (NTRB) This Morning While It's Still Early
With a raised $15 target from Noble Capital Markets, a float under 4.5M shares, and fresh inclusion in several Russell indexes just yesterday, (NTRB) could be popping onto more screens. The last two times we covered (NTRB), it moved approximately 31% and 42% in short windows, showing how quickly attention can shift. Now, with Barchart highlighting 13 out of 13 bullish signals, the technical sentiment is hard to ignore. With patent-backed protection in 46 countries and a milestone manufacturing step completed for AVERSA™ Fen-tan-yl, (NTRB) is now preparing for its next phase. And now it's back on our radar. We have all eyes on (NTRB) this morning. Pull up (NTRB) while it's still early. Breaking: 25% Preferred Dividend Declared as AVERSA FDA Filing Targeted Shareholders on record as of July 25, 2025 will receive a 25% preferred stock dividend, with one preferred share for every four common shares, payable August 5. Watch for my next update—it could be out very shortly. Sincerely, Alex Ramsay
Co-Founder / Managing Editor Krypton Street Newsletter
| 
No comments:
Post a Comment